AstraZeneca
Teva’s Nexium copycat approved in US
January 27, 2015Manufacturing and Production, Sales and Marketing AstraZeneca, Teva, esomeprazole, gerd, heart, nsaids
Teva has won approval for its copycat form of AstraZeneca’s big-selling heatburn drug Nexium, making it the first generic version …
Bioscience lab opens up in Cambridge
January 20, 2015Research and Development AstraZeneca, BIA, Babraham Research Campus, Cambridge, Menelas Pangalos
The UK Bennet Building bioscience laboratory doors have been opened during a ceremony at the Babraham Research Campus in Cambridge …
Astellas takes senior head from AstraZeneca
January 19, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, AstraZeneca, eric Terhaerdt
Eric Terhaerdt has been named as the senior vice president of global development operations at Astellas Pharma. Terhaerdt, who joins the …
AstraZeneca’s troubled Brilinta gets welcome lift
January 14, 2015Sales and Marketing AstraZeneca, Brilinta, FDA, US Department of Justice, acute coronary syndrome, ticagrelor
AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart …
AstraZeneca drops CDF application
January 12, 2015Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib
AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …
AstraZeneca ovarian cancer drug approved in Europe
December 18, 2014Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian
The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …
AstraZeneca closing US manufacturing unit
December 16, 2014Manufacturing and Production, Sales and Marketing AstraZeneca, Pulmicort, malloy, short haircuts, westboro
AstraZeneca is closing its Otis Street manufacturing plant next year that has been in operation for 33 years, and the …
Pharma to lose $69 billion in five years as patents expire
December 12, 2014Sales and Marketing AstraZeneca, GlobalData, Japanese firm Otsuka, Otsuka, lilly, pharma
Pharma companies are set to lose around $65 billion by 2019 due to drug patent expiries according to research firm …
AstraZeneca constipation drug gets EU nod
December 9, 2014Sales and Marketing AstraZeneca, KODIAC, NKTR-118, PAMORA, moventig, naloxegol
AstraZeneca’s opioid-induced constipation drug Moventig has been approved by the European Commission. The first once-daily PAMORA tablet to be given …
AZ triumphs in Nexium pay-for-delay trial
December 8, 2014Sales and Marketing AstraZeneca, Dr Reddy's, Nexium, Ranbaxy, dr reddys, esomeprazole
AstraZeneca and Ranbaxy have avoided what might have been a $10 billion pay out regarding delays to the generic version …
AZ and Lilly Alzheimer’s drug enters trials
December 1, 2014Research and Development, Sales and Marketing AZD3293, Alzheimer's, AstraZeneca, LY3314814, lilly
AstraZeneca and Eli Lilly have begun a Phase II/II trial for their Alzheimer’s treatment AZD3293 as the companies hope to …
CRUK and AZ collaborate on cancer screening
November 28, 2014Research and Development, Sales and Marketing AstraZeneca, CRUK, Cambridge, Cancer, Cancer Research UK, MRC
Cancer Research UK (CRUK) scientists are to be given access to drug discovery facilities at AstraZeneca’s Cambridge site as part …
AZ predicts strong growth ahead of Pfizer deadline
November 19, 2014Sales and Marketing AZD9291, AstraZeneca, Pfizer, Soriot, definiens
AstraZeneca has announced that it expects to deliver revenues of over $45 billion by 2023 as it makes its final …
Numerous prospects in health technology say analysts
November 12, 2014Medical Communications, Sales and Marketing 3D, AstraZeneca, F&S, app, digital, frost and sullivan, fs, wearables
Medical devices and imaging technology have been included in a recent analysis of the top 50 most innovative technologies. Frost …
AstraZeneca diabetes drug approved for use in Scotland
November 11, 2014Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2
The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
